Vancouver, BC, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Trident Resources Corp. (TSXV: ROCK) (OTCQB: TRDTF) (“Trident” or the “Company”) is pleased to announce additional positive diamond drill results from a further ten holes during its autumn 2025 drill program at the Contact Lake Project. To date, the company has released assay results from thirteen holes out of the total nineteen holes drilled. The holes that are reported in this release were all collared northeast of the existing underground mine infrastructu ...

Accomplished chemical engineer to support design and integration of experimental results into ThermoLoop process models Santa Clarita, California, Jan. 13, 2026 (GLOBE NEWSWIRE) -- NewHydrogen, Inc. (OTCQB:NEWH), the developer of ThermoLoop™, a breakthrough technology that uses water and heat rather than renewable electricity to produce the world’s cheapest clean hydrogen, today announced the appointment of Ryan Patrick as Senior Chemical Engineer. Patrick's work with NewHydrogen supports the development of ...

Vancouver, BC, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Trident Resources Corp. (TSXV: ROCK) (OTCQB: TRDTF) (“Trident” or the “Company”) is pleased to announce additional positive diamond drill results from a further ten holes during its autumn 2025 drill program at the Contact Lake Project. To date, the company has released assay results from thirteen holes out of the total nineteen holes drilled. The holes that are reported in this release were all collared northeast of the existing underground mine infrastructu ...

Key Takeaways BNY is set to report Q4 results Jan. 13, with revenues and earnings expected to rise y/y.BK's fee revenues are projected to grow, led by investment services fees, making up over half of revenues.BK's NII is expected to increase despite rate cuts, supported by loan growth and stable funding costs.The Bank of New York Mellon Corporation (BK) is scheduled to report fourth-quarter and 2025 results on Jan. 13, before market open. The company’s quarterly revenues and earnings are expected to have in ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

ACG doubles its 737-10 order book with purchase of 25 additional jets as well as additional order for 25 737-8s 737-10 order is single biggest order for the aircraft type by a lessor SEATTLE, Jan. 13, 2026 /PRNewswire/ -- Boeing [NYSE: BA] and Aviation Capital Group LLC (ACG) announced today the airplane lessor has placed a new order for 50 737 MAX jets, including 25 737-8 and 25 737-10 airplanes. Continue Reading Aviation Capital Group doubles its 737-10 order book with purchase of 25 addition ...

Core Viewpoint - Madrigal Pharmaceuticals is positioned as a leading company in the metabolic and liver disease sector, with significant accomplishments over the past two years and a strong outlook for the future [2][3]. Company Overview - Madrigal Pharmaceuticals has been recognized as one of the most consequential companies in the metabolic and liver disease space in recent years [2]. - The company is led by CEO Bill Sibold, CMO Dr. David Soergel, and CFO Mardi Dier, who are actively engaging with stakeholders to provide updates on the company's progress [2]. Strategic Focus - The company's primary mission is to lead the fight against MASH (Metabolic Associated Steatotic Hepatitis), which reflects its commitment to addressing critical health challenges in this area [4]. - Madrigal emphasizes the importance of leadership and innovation in its approach to tackling MASH, aiming to differentiate itself within the industry [4].

Core Viewpoint - A U.S. judge has allowed Orsted to resume work on the nearly finished Revolution Wind project, leading to a nearly 6% rise in the company's shares [1]. Group 1: Project Overview - The Revolution Wind project is a $5 billion initiative located about 15 miles south of the Rhode Island coast, developed as a 50/50 joint venture between Orsted and Global Infrastructure Partners' Skyborn Renewables [2]. - Orsted and Skyborn Renewables have reported that they have already invested approximately $5 billion into the Revolution Wind project [2]. Group 2: Legal Context - The ruling represents a legal setback for the Trump administration, which had attempted to block the Revolution Wind project [2].

Core Insights - Nxera Pharma has received a milestone payment of US$3.6 million from Centessa Pharmaceuticals due to the achievement of an early development milestone for the investigational drug ORX142, which is aimed at treating neurological and neurodegenerative disorders [1] - The milestone payment will be recognized as revenue in Q4 FY2025 [1] Company Overview - Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines to address unmet medical needs in Japan and globally [3] - The company operates a new-generation commercial business in Japan, developing and commercializing innovative medicines, with several products already launched [3] - Nxera Pharma utilizes its proprietary NxWave™ GPCR structure-based drug discovery platform to advance a comprehensive pipeline, both internally and in collaboration with leading pharmaceutical and biotech companies [3] - The company has key operational locations in Tokyo, Osaka, London, Cambridge, Basel, and Seoul, and is listed on the Tokyo Stock Exchange under the ticker 4565 [3]